The just released data from my study: 70% remain in remission, higher than any other treatment for MS. Page two of the Medscape article is most interesting, going into detail about the trial including the adverse events (399), and a question of what to do with the non-responders at year 5. Am I bummed about falling into the 30% category? A little, but that's life with this disease: no guarantees. - D
-------------
HALT-MS: Stem Cell Transplant Durable at 5 Years in MS
NATIONAL HARBOR, Maryland — Most recent data from a small, phase 2 study of autologous hematopoietic cell transplantation for multiple sclerosis shows that two thirds of the patients had a sustained remission of disease 5 years after transplant.
Sixty-nine percent of patients met the primary endpoint of event-free survival.
"That's certainly much higher than any other treatment to this point," Michael K. Racke, MD, professor of neurology and neuroscience at Wexner Medical Center at The Ohio State University in Columbus, told Medscape Medical News.
Dr Racke is an investigator in the HALT-MS (High-dose Immunosuppression and Autologous Stem Cell Transplantation for Poor Prognosis Multiple Sclerosis) trial). http://www.halt-ms.org/
FULL ARTICLE
http://www.medscape.com/viewarticle/864443#vp_1
-------------
HALT-MS: Stem Cell Transplant Durable at 5 Years in MS
NATIONAL HARBOR, Maryland — Most recent data from a small, phase 2 study of autologous hematopoietic cell transplantation for multiple sclerosis shows that two thirds of the patients had a sustained remission of disease 5 years after transplant.
Sixty-nine percent of patients met the primary endpoint of event-free survival.
"That's certainly much higher than any other treatment to this point," Michael K. Racke, MD, professor of neurology and neuroscience at Wexner Medical Center at The Ohio State University in Columbus, told Medscape Medical News.
Dr Racke is an investigator in the HALT-MS (High-dose Immunosuppression and Autologous Stem Cell Transplantation for Poor Prognosis Multiple Sclerosis) trial). http://www.halt-ms.org/
FULL ARTICLE
http://www.medscape.com/viewarticle/864443#vp_1
Comment